Alector Inc (NAS:ALEC)
$ 4.57 -0.09 (-1.93%) Market Cap: 444.75 Mil Enterprise Value: -14.68 Mil PE Ratio: 0 PB Ratio: 2.95 GF Score: 62/100
Back to the Transcripts List

Q2 2024 Alector Inc Earnings Call Transcript

Aug 07, 2024 / 08:30PM GMT
Release Date Price: $4.91 (-2.96%)

Key Points

Positve
  • Alector Inc (ALEC) has a strong cash position of $503.3 million, extending its runway through 2026.
  • The company is on track for the AL002 Phase 2 trial INVOKE-2 data readout in Q4 2024.
  • AL002 has shown robust target engagement and increased microglial signaling in Phase 1 studies.
  • The FDA granted breakthrough therapy designation to Latozinemab for the potential treatment of FTD with GRN limitations.
  • Alector Inc (ALEC) introduced the Alector Brain Carrier (ABC) platform, enhancing drug delivery across the blood-brain barrier.
Negative
  • The INVOKE-2 trial has seen MRI findings resembling amyloid-related imaging abnormalities (ARIA), particularly in APOE4 homozygotes.
  • Enrollment in the PROGRESS-AD global Phase 2 clinical trial of AL101 is ongoing, indicating potential delays.
  • The company faces challenges in demonstrating clinical efficacy for AL002, which may not reach the 24 centiloid level necessary for clinical efficacy seen in anti-amyloid antibodies.
  • The long-term extension study for INVOKE-2 remains blinded, potentially delaying the full understanding of the drug's efficacy and safety.
  • Alector Inc (ALEC) has not yet disclosed which programs in its earlier portfolio will advance next, creating uncertainty about future developments.
Operator

Good afternoon, ladies and gentlemen, and welcome to the Alector Second Quarter and Midyear 2024 Earnings Conference Call. At this time, all participants are in listen-only mode. After the speakersâ presentation, there will be a question-and-answer session. (Operator Instructions) As a reminder, this conference call is being recorded.

I would now like to turn the call over to Katie Hogan, Senior Director of Corporate Communications and Investor Relations. Please go ahead.

Kate Hogan
Alector Inc - Senior Director, Corporate Communications and Investor Relations

Thank you, operator, and hello, everyone. Earlier this afternoon, we released our financial results for the second quarter 2024. The press release is available on our website at www.alector.com, and our 10-Q was filed with the Securities and Exchange Commission this afternoon.

Joining me on the call today are Dr. Arnon Rosenthal, Co-Founder and CEO; Dr. Sara Kenkare-Mitra, President and Head of Research and Development; Dr

Already have an account? Log in
Get the full story
Start 7-Day Free Trial
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot
Research Tools
All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board
Product
Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文
Education
Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation
Company
About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program
Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey
Follow Us
download GuruFocus on Apple store download GuruFocus on Google Play
Disclaimers
GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.
© 2004-2024 GuruFocus.com, LLC. All Rights Reserved.